Compass sued Zillow in June over its listing access standards, which threatened to ban listings that were not uploaded to its platform within 24 hours of being publicly marketed. Last month, a judge ...

Property brokerage Compass on Wednesday dropped its lawsuit against Zillow, ending a legal clash over how home listings can be marketed online. For the past few years, Compass — now the largest real ...

Brokerage Compass dropped its lawsuit against Zillow after the listings giant said it would allow some pre-marketed homes on its platform, ending a multi-month fight between two real estate giants ...

What You Need to Know About the New 2026 Jeep Compass - Find the best Jeep Compass deals! The Jeep brand is known for crafting vehicles that excel on fire roads. The Compass is the most affordable ...

Compass, the largest residential real estate brokerage in the United States by sales volume, plans to lay off 110 employees in Madison in 2026. The company filed a WARN notice with the New Jersey ...

At the start of the month, Inman broke news regarding executive personnel changes at Anywhere. CEO Ryan Schneider and Chief Technology Officer Rudy Wolfs both exited the company, the publication ...

Compass’ fourth-quarter earnings call this week came with more than bottom-line metrics. The company announced a three-year partnership with Rocket and Redfin. The “strategic alliance,” as Compass ...

Rogers Healy is out of the real estate game. The venture capitalist and residential real estate mogul has merged his Dallas-based brokerage, Rogers Healy and Associates Real Estate, into New ...

Compass International Holdings (CIH), the parent company of real estate brokerage Compass, is teaming up with Rocket Companies and Redfin to display its Compass Coming Soon listings for Redfin’s 60 ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

COMP360 shows rapid symptom improvement in depression study COMP360 may compete with J&J's Spravato if approved Compass plans FDA meeting for rolling submission Feb 17 (Reuters) - Compass Pathways ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...